Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (BLOOM)
This study has been completed.
Study NCT00613002   Information provided by BioSante Pharmaceuticals

First Received on January 30, 2008.   Last Updated on January 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypoactive Sexual Desire Disorder
Additional conditions recognized in this trial
Hypokinesia
Sexual Dysfunctions, Psychological
More general conditions related to this trial
Dyskinesias
Mental Disorders
Nervous System Diseases
Neurologic Manifestations
Sexual and Gender Disorders
Signs and Symptoms
Interventions listed in this trial
testosterone gel
placebo gel
Additional drug interventions recognized in this trial
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
More general drug interventions related to this trial
Anabolic Agents
Androgens
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
BioSante Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services